Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer
Immunome, Inc. (IMNM)
Company Research
Source: Business Wire
Co-founder Susan Dillon, Ph.D., to remain as the chair of Board of Directors PHILADELPHIA--(BUSINESS WIRE)--Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent, targeted short-interfering RNA (siRNA) medicines, today announced that its co-founder, Susan Dillon, Ph.D., will transition from her position as president and chief executive officer (CEO) and continue as chair of the Board of Directors and advisor to the company. As part of the planned leadership transition, Aro appointed industry veteran Purnanand Sarma, Ph.D., as the CEO and a member of the Board, effective immediately.“We founded Aro with the vision to create a new class of targeted siRNA medicines to address significant clinical needs with a fundamentally new approach for the most intractable diseases. As we rapidly build our pipeline, with our lead program already in clinical testing in patients, we believe the time is right for new leadership to guide the next stages of Aro’s growth,
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat [Seeking Alpha]Seeking Alpha
- Immunome prices $400M stock offering at $21.50 a share [Seeking Alpha]Seeking Alpha
- Stock Market Today: Russell 2000, Nasdaq Saddle Tech Pullback Ahead of Big Week of Data [Yahoo! Finance]Yahoo! Finance
- Immunome Announces Pricing of Public Offering of Common Stock [Yahoo! Finance]Yahoo! Finance
- Immunome Announces Pricing of Public Offering of Common StockBusiness Wire
IMNM
Earnings
- 8/6/25 - Beat
IMNM
Sec Filings
- 12/18/25 - Form 4
- 12/17/25 - Form 8-K
- 12/17/25 - Form 424B5
- IMNM's page on the SEC website